<code id='F9AC825E50'></code><style id='F9AC825E50'></style>
      • <acronym id='F9AC825E50'></acronym>
      <center id='F9AC825E50'><center id='F9AC825E50'><tfoot id='F9AC825E50'></tfoot></center><abbr id='F9AC825E50'><dir id='F9AC825E50'><tfoot id='F9AC825E50'></tfoot><noframes id='F9AC825E50'>
      • <optgroup id='F9AC825E50'><strike id='F9AC825E50'><sup id='F9AC825E50'></sup></strike><code id='F9AC825E50'></code></optgroup>
        5. <b id='F9AC825E50'><label id='F9AC825E50'><select id='F9AC825E50'><dt id='F9AC825E50'><span id='F9AC825E50'></span></dt></select></label></b><u id='F9AC825E50'></u>
          <i id='F9AC825E50'><strike id='F9AC825E50'><tt id='F9AC825E50'><pre id='F9AC825E50'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / entertainment / knowledge      
           
     
           
      
          knowledge 
           
      
           
      
           
       2025-08-03 11:18:10 
   
      
           
      
           
                        
          knowledge  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：5
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups.
          The bank announced Wednesday that it has closed its first-ever life sciences fund, called West Street Life Sciences I. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.
          advertisement
          First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. Around $25.6 billion had been raised by 556 first-time funds in 2022.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          How artificial intelligence is being used to detect, treat cancer
                                
                            
          Next article：  
                                      
                                          At least 13 dead in Texas as scorching temps continue
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles